Newsfeed | Navigating EGFR

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Read more about RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer Published on 05/29/2026 at 02:02 pm EDT PRNewswire Share JOHNSON & JOHNSON -2.37%Median overall survival, a secondary endpoint, reached nearly...

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Read more about RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

This is a paid press release. Contact the press release distributor directly with any inquiries. RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer PR Newswire Fri, May 29,...

Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

Read more about Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

ZEGFROVY作为携带EGFRexon20ins突变的晚期非小细胞肺癌（NSCL...

ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

Read more about ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins WU-KONG28 is the first global randomized phase 3 study with positive results for an oral, chemo-free, targeted monotherapy regimen in first-line...

Dissecting the disconnect between circuit activation and dominant adaptive evolution in cytoplasmic phage-assisted continuous evolution (PACE) of an EGFR nanobody

Read more about Dissecting the disconnect between circuit activation and dominant adaptive evolution in cytoplasmic phage-assisted continuous evolution (PACE) of an EGFR nanobody

IntroductionCytoplasmic phage-assisted continuous evolution (PACE) is widely used due to its low selection pressure and straightforward circuit design. Howev Abstract Introduction: Cytoplasmic phage-assisted continuous evolution (PACE) is widely used due to its low selection pressure and straightforward circuit design. However,...

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China

Read more about Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China

ArticlesVolume 96103994June 2026Open accessDownload Full Issue Download started OkNeoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in ChinaChao Zhanga,b,g ∙ Ben-Yuan Jianga,b,g ∙ Li-Xu Yanc ∙ Li-Shan Penga,b ∙ Jin-Hu...

Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States

Read more about Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States

AbstractBackground and Objective Real option value (ROV) remains underexplored in epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for non-small cell lung cancer (NSCLC) even though its impact on economic evaluation is being acknowledged. The objective of this study is to...

Unexpected elevation of β-hCG in EGFR-mutant lung adenocarcinoma: a case study and implications for clinical practice

Read more about Unexpected elevation of β-hCG in EGFR-mutant lung adenocarcinoma: a case study and implications for clinical practice

AbstractBackground Beta-human chorionic gonadotropin (β-hCG) is frequently overexpressed in germ cell and trophoblastic tumors as well as various solid tumors; however, the presence of high levels of serum β-hCG is very rare in patients with non-small cell lung cancer. Case...

H4K8 lactylation-mediated ferroptosis defense drives EGFR-TKI resistance in lung adenocarcinoma

Read more about H4K8 lactylation-mediated ferroptosis defense drives EGFR-TKI resistance in lung adenocarcinoma

Abstract Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains a major clinical challenge in non-small cell lung cancer. Emerging evidence indicates that metabolic reprogramming and epigenetic alterations contribute to drug resistance, particularly through the evasion...

Subscribe to Newsfeed